The similarities in phenotypes observed in the MS model and in NOD mice infected with CB4 in the context of TGF-β suggest that glatiramer acetate treatment may represent a potential therapeutic avenue for the treatment of T1D. This evidence concerns the gene TGFB1 and type 1 diabetes mellitus.